These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 28289017)

  • 1. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
    Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
    Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
    Yaoita N; Satoh K; Satoh T; Sugimura K; Tatebe S; Yamamoto S; Aoki T; Miura M; Miyata S; Kawamura T; Horiuchi H; Fukumoto Y; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1293-301. PubMed ID: 27102961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
    Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
    Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAR-2 inhibition reverses experimental pulmonary hypertension.
    Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
    Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.
    Abid S; Houssaïni A; Mouraret N; Marcos E; Amsellem V; Wan F; Dubois-Randé JL; Derumeaux G; Boczkowski J; Motterlini R; Adnot S
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):304-12. PubMed ID: 24334871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
    van Moorsel MVA; Poolen GC; Koekman CA; Verhoef S; de Maat S; Barendrecht A; van Kleef ND; Meijers JCM; Schiffelers RM; Maas C; Urbanus RT
    J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
    Qin L; D'Alessandro-Gabazza CN; Aoki S; Gil-Bernabe P; Yano Y; Takagi T; Boveda-Ruiz D; Ramirez Marmol AY; San Martin Montenegro VT; Toda M; Miyake Y; Taguchi O; Takei Y; Morser J; Gabazza EC
    J Thromb Haemost; 2010 Apr; 8(4):808-16. PubMed ID: 20088932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of LR11 Attenuates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation With Medial Thickening in Mice.
    Jiang L; Konishi H; Nurwidya F; Satoh K; Takahashi F; Ebinuma H; Fujimura K; Takasu K; Jiang M; Shimokawa H; Bujo H; Daida H
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1972-9. PubMed ID: 27493099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension.
    Kong D; Liu J; Lu J; Zeng C; Chen H; Duan Z; Yu K; Zheng X; Zou P; Zhou L; Lv Y; Zeng Q; Lu L; Li J; He Y
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):e172-e195. PubMed ID: 38572649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
    Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
    Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors.
    Gils A; Ceresa E; Macovei AM; Marx PF; Peeters M; Compernolle G; Declerck PJ
    J Thromb Haemost; 2005 Dec; 3(12):2745-53. PubMed ID: 16359512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
    Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
    J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
    J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
    Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
    J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB
    BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble JAGGED1 inhibits pulmonary hypertension by attenuating notch signaling.
    Xiao Y; Gong D; Wang W
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2733-9. PubMed ID: 24072692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
    Myles T; Nishimura T; Yun TH; Nagashima M; Morser J; Patterson AJ; Pearl RG; Leung LL
    J Biol Chem; 2003 Dec; 278(51):51059-67. PubMed ID: 14525995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.